Completed PHASE4 INTERVENTIONAL NCT00141427

Pregabalin In Partial Seizures: An Open-Label, International, Multicenter Add-On Therapy Trial.

Pregabalin In Partial Seizures (Preps) : An Open-Label, International, Multicenter Add-On Therapy Trial

Sponsor: Pfizer's Upjohn has merged with Mylan to form Viatris Inc.

Conditions Seizures

Interventions Pregabalin

Updated 7 times since 2017 Last updated: Jan 21, 2021 Started: Nov 30, 2004 Completion: May 31, 2006

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE4 clinical study on Seizures, this trial is completed. The trial is conducted by Pfizer's Upjohn has merged with Mylan to form Viatris Inc. and has accumulated 7 data snapshots since 2004. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

7 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE4
Sep 2024 — Sep 2025 [monthly]

Completed PHASE4
Jul 2024 — Sep 2024 [monthly]

Completed PHASE4
Feb 2021 — Jul 2024 [monthly]

Completed PHASE4
Jan 2021 — Feb 2021 [monthly]

Completed PHASE4

▶ Show 2 earlier versions

Jun 2018 — Jan 2021 [monthly]

Completed PHASE4
Jan 2017 — Jun 2018 [monthly]

Completed PHASE4

First recorded

Nov 2004

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Pfizer's Upjohn has merged with Mylan to form Viatris Inc.

Data source: Pfizer

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Alkmaar, Netherlands , Bayonne, France , Bordeaux, France , Braga, Portugal , Breda, Netherlands , Bruges, Belgium , Brussels, Belgium , Cambridge, United Kingdom , Duffel, Belgium , Funchal, Portugal and 40 more locations